Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Amphetamine-Related Disorders
Intervention: Bupropion (Drug)
Phase: Phase 1
Status: Active, not recruiting
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Thomas Newton, M.D., Principal Investigator, Affiliation: National Institute on Drug Abuse (NIDA)
Summary
The purpose of this study is to assess potential interactions between intravenous (IV)
methamphetamine and oral bupropion.
Clinical Details
Official title: Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between IV Methamphetamine and Oral Bupropion
Study design: Diagnostic, Randomized, Double-Blind, Placebo Control
Primary outcome: Psychological effectsBP, HR
Detailed description:
This is a human laboratory clinical pharmacology study to assess potential interactions
between IV methamphetamine challenge and treatment with oral sustained-release bupropion.
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Please contact site director for more details.
Exclusion Criteria:
Please contact site director for more details.
Locations and Contacts
UCLA Integrated Substance Abuse Program, Los Angeles, California 90024, United States
University of Texas Health Science Center, Houston, Texas 77225, United States
Additional Information
Starting date: June 2002
Ending date: September 2003
Last updated: February 8, 2007
|
